Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Common Equity: 2010-2025

Historic Common Equity for Sunshine Biopharma (SBFM) over the last 11 years, with Sep 2025 value amounting to $24.2 million.

  • Sunshine Biopharma's Common Equity fell 3.35% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year decrease of 3.35%. This contributed to the annual value of $23.5 million for FY2024, which is 10.81% up from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Common Equity is $24.2 million, which was down 5.78% from $25.7 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Common Equity ranged from a high of $41.9 million in Q2 2022 and a low of -$1.2 million during Q3 2021.
  • Its 3-year average for Common Equity is $23.2 million, with a median of $23.5 million in 2024.
  • As far as peak fluctuations go, Sunshine Biopharma's Common Equity spiked by 10,117.97% in 2022, and later tumbled by 45.61% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Common Equity (Quarterly) stood at $211,662 in 2021, then surged by 10,117.97% to $21.6 million in 2022, then decreased by 1.94% to $21.2 million in 2023, then climbed by 10.81% to $23.5 million in 2024, then fell by 3.35% to $24.2 million in 2025.
  • Its last three reported values are $24.2 million in Q3 2025, $25.7 million for Q2 2025, and $22.7 million during Q1 2025.